{"product_id":"memorial-sloan-kettering-cancer-center-foundations-in-immunotherapy-in-the-oncology-population-2026","title":"Memorial Sloan Kettering Cancer Center Foundations in Immunotherapy in the Oncology Population 2026","description":"\u003ch2\u003eMemorial Sloan Kettering Cancer Center Foundations in Immunotherapy in the Oncology Population 2026\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003eComplete Immuno-Oncology Training | CAR T-Cell, Checkpoint Inhibitors \u0026amp; Toxicity Management\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch3\u003e📌 Overview\u003c\/h3\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eThe \u003cstrong\u003eMemorial Sloan Kettering Cancer Center (MSKCC) Foundations in Immunotherapy 2026\u003c\/strong\u003e is a comprehensive, evidence-based course designed to provide clinicians with a strong foundation in modern cancer immunotherapy.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eThis program covers the \u003cstrong\u003emechanisms, clinical applications, and toxicity management\u003c\/strong\u003e of immunotherapeutic agents across both \u003cstrong\u003esolid tumors and hematologic malignancies\u003c\/strong\u003e, with a strong focus on real-world clinical practice.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eDeveloped by experts at one of the world’s leading cancer centers, this course equips healthcare professionals with the knowledge needed to safely and effectively integrate immunotherapy into patient care .\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch3\u003e📦 Course Specifications\u003c\/h3\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eVideos:\u003c\/strong\u003e 23 HD lectures\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eSubtitles:\u003c\/strong\u003e 23 VTT files\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003ePDFs:\u003c\/strong\u003e 20 supporting documents\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eTotal Size:\u003c\/strong\u003e 4.97 GB\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eFormat:\u003c\/strong\u003e On-demand learning\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eCourse Date:\u003c\/strong\u003e January 28, 2026\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch3\u003e🎯 Target Audience\u003c\/h3\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eThis course is ideal for:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eMedical oncologists\u003c\/li\u003e\r\n \t\u003cli\u003eHematologists\u003c\/li\u003e\r\n \t\u003cli\u003eOncology fellows and residents\u003c\/li\u003e\r\n \t\u003cli\u003eNurse practitioners and physician assistants in oncology\u003c\/li\u003e\r\n \t\u003cli\u003eMultidisciplinary cancer care teams\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch3\u003e🧠 What You Will Learn\u003c\/h3\u003e\r\n\u003ch4\u003e🧬 Foundations of Immunotherapy\u003c\/h4\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eImmune system mechanisms in cancer\u003c\/li\u003e\r\n \t\u003cli\u003eInnate vs adaptive immune responses\u003c\/li\u003e\r\n \t\u003cli\u003eMechanisms of immune checkpoint blockade\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e💉 Checkpoint Inhibitors \u0026amp; Targeted Therapies\u003c\/h4\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003ePD-1, PD-L1, and CTLA-4 inhibitors\u003c\/li\u003e\r\n \t\u003cli\u003eNovel checkpoint inhibitors and combinations\u003c\/li\u003e\r\n \t\u003cli\u003eClinical applications across multiple cancers\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e🧫 CAR T-Cell \u0026amp; Cellular Therapy\u003c\/h4\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eCAR T-cell therapy principles and indications\u003c\/li\u003e\r\n \t\u003cli\u003ePatient selection and outcomes\u003c\/li\u003e\r\n \t\u003cli\u003eToxicities: CRS, ICANS, cytopenias\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e🔬 Emerging Immunotherapies\u003c\/h4\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eBispecific antibodies (BiTEs)\u003c\/li\u003e\r\n \t\u003cli\u003eTumor-infiltrating lymphocytes (TILs)\u003c\/li\u003e\r\n \t\u003cli\u003eNovel immune agonists and IL-2 agents\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e⚠️ Toxicity \u0026amp; Adverse Event Management\u003c\/h4\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eImmune-related adverse events (irAEs)\u003c\/li\u003e\r\n \t\u003cli\u003ePneumonitis, dermatologic toxicity, neurotoxicity\u003c\/li\u003e\r\n \t\u003cli\u003eEvidence-based management strategies\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e🧠 Clinical Application \u0026amp; Case-Based Learning\u003c\/h4\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eReal-world case discussions\u003c\/li\u003e\r\n \t\u003cli\u003eTreatment planning and decision-making\u003c\/li\u003e\r\n \t\u003cli\u003ePersonalized immunotherapy approaches\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch3\u003e📚 Course Topics Include\u003c\/h3\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eCAR T-cell therapy advancements\u003c\/li\u003e\r\n \t\u003cli\u003eImmunotherapy in leukemia, lymphoma, and myeloma\u003c\/li\u003e\r\n \t\u003cli\u003eBladder, breast, melanoma, and GI cancers\u003c\/li\u003e\r\n \t\u003cli\u003eSmall cell lung cancer immunotherapy\u003c\/li\u003e\r\n \t\u003cli\u003eDermatologic and pulmonary toxicities\u003c\/li\u003e\r\n \t\u003cli\u003eNeurotoxicity and immune complications\u003c\/li\u003e\r\n \t\u003cli\u003eBispecific immune-modulating agents\u003c\/li\u003e\r\n \t\u003cli\u003eCheckpoint inhibitor strategies\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch3\u003e⚡ Key Benefits\u003c\/h3\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eMaster \u003cstrong\u003emodern immunotherapy principles and applications\u003c\/strong\u003e\n\u003c\/li\u003e\r\n \t\u003cli\u003eImprove \u003cstrong\u003epatient selection and treatment outcomes\u003c\/strong\u003e\n\u003c\/li\u003e\r\n \t\u003cli\u003eRecognize and manage \u003cstrong\u003eserious immunotherapy toxicities\u003c\/strong\u003e\n\u003c\/li\u003e\r\n \t\u003cli\u003eStay updated with \u003cstrong\u003elatest oncology advances\u003c\/strong\u003e\n\u003c\/li\u003e\r\n \t\u003cli\u003eApply knowledge directly in clinical practice\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch3\u003e🚀 Why Choose This Course\u003c\/h3\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eDeveloped by \u003cstrong\u003eworld-leading MSKCC experts\u003c\/strong\u003e\n\u003c\/li\u003e\r\n \t\u003cli\u003eCovers both \u003cstrong\u003efoundations and advanced updates\u003c\/strong\u003e\n\u003c\/li\u003e\r\n \t\u003cli\u003eFocus on \u003cstrong\u003epractical, real-world oncology care\u003c\/strong\u003e\n\u003c\/li\u003e\r\n \t\u003cli\u003eEssential for clinicians using or planning immunotherapy\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch3\u003e💡 Clinical Value\u003c\/h3\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eThis course is essential for healthcare professionals who want to:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eIntegrate \u003cstrong\u003eimmunotherapy safely into oncology practice\u003c\/strong\u003e\n\u003c\/li\u003e\r\n \t\u003cli\u003eImprove outcomes in \u003cstrong\u003esolid and hematologic cancers\u003c\/strong\u003e\n\u003c\/li\u003e\r\n \t\u003cli\u003eStay current with \u003cstrong\u003erapidly evolving cancer treatments\u003c\/strong\u003e\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch3\u003e🏥 About MSKCC\u003c\/h3\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eMemorial Sloan Kettering Cancer Center is one of the world’s leading cancer institutions, dedicated to advancing cancer treatment through research, education, and clinical excellence.\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n \r\n\u003ch2 data-path-to-node=\"6\"\u003e4. Topics\u003c\/h2\u003e\r\n\u003col start=\"1\" data-path-to-node=\"8\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,0,0\"\u003eAdvancing CAR T-Cell Strategies and Combination Therapies to Improve Outcomes in Gynecologic Malignancies\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,1,0\"\u003eAdvancing Leukemia Care Through Immuno-Oncology\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,2,0\"\u003eApproaches to Immunotherapy-related Pneumonitis Management\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,3,0\"\u003eBreast Oncology- Using cfDNA to Forecast Immunotherapy Treatment Outcomes\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,4,0\"\u003eCheckpoint Inhibition as a Therapeutic Approach in Advanced Hodgkin Lymphoma\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,5,0\"\u003eClinical Approaches to Dermatologic Toxicity in Checkpoint Inhibitor Therapy\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,6,0\"\u003eDiscussion of Novel Checkpoint Inhibitors and Combination Therapy\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,7,0\"\u003eDostarlimab in MSI-High Gastrointestinal Cancers- Latest Data, Expansion Cohorts, and Basket Trial Insights\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,8,0\"\u003eEvolving Treatment Paradigms- Immunotherapy in Advanced Bladder Cancer\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,9,0\"\u003eIL-2-Stimulating Agents from Early Drug Development\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,10,0\"\u003eInnovations in Small Cell Lung Cancer- DLL3 Agents and Adjuvant Durvalumab\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,11,0\"\u003eIntrathecal Immunotherapy- A Novel Path in Treating Leptomeningeal Disease no video\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,12,0\"\u003eMechanism of Action of Checkpoint Blockade PD1, PDL1, CTLA-4\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,13,0\"\u003eMelanoma Subtypes are a Microcosm for Immune Checkpoint Blockade Efficacy Across Oncology-\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,14,0\"\u003eNeurotoxicity in CAR T-Cell Therapy- Recognition and Management\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,15,0\"\u003eOverview of Adverse Events in the Cell Therapy Patient- A Discussion of CRS, ICANS, and Prolonged Cytopenias\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,16,0\"\u003eQ\u0026amp;A and Discussion – 01\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,17,0\"\u003eQ\u0026amp;A and Discussion – 02\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,18,0\"\u003eQ\u0026amp;A and Discussion – 03\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,19,0\"\u003eQ\u0026amp;A and Discussion – 04\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,20,0\"\u003eQ\u0026amp;A and Discussion\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,21,0\"\u003eTargeting Multiple Myeloma with Bispecific Immune-Modulating Agents\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,22,0\"\u003eThe Role of T-Cell Therapy in Standard Care for Synovial Sarcoma\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,23,0\"\u003eUnderstanding Chimeric Antigen Receptor (CAR) T-Cell Therapy\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ol\u003e","brand":"Amboss","offers":[{"title":"Default Title","offer_id":42954708648034,"sku":"MED-AMB08591","price":35.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/Memorial-Sloan-Kettering-Cancer-Center-Foundations-in-Immunotherapy-in-the-Oncology-Population-2026_15720874-57e0-4050-9116-aaba1a53a69c.jpg?v=1779382874","url":"https:\/\/meducourse.com\/products\/memorial-sloan-kettering-cancer-center-foundations-in-immunotherapy-in-the-oncology-population-2026","provider":"Meducourse","version":"1.0","type":"link"}